格列齐特普通片改为格列齐特缓释片治疗2型糠尿病临床观察.docVIP

格列齐特普通片改为格列齐特缓释片治疗2型糠尿病临床观察[摘要] 目的：评价服用格列齐特缓释剂 （格列齐特释片30 mg片剂）治疗12周后，对2型糖尿病患者总体控制的有效性，并与普通剂型比较。方法：100例2型糖尿病患者随机分为两组治疗，一组为开始使用单纯格列齐特普通制剂，在观察开始时改为使用格列齐特缓释剂组，一组为普通剂型格列齐特组。治疗12周后以其两组的糖基化血红蛋白（HbA1c），空腹血浆葡萄糖各自的对比，评价服用格列齐特缓释片对2型糖尿病的有效性及对比普通制剂的优越性。同时通过对副作用，特别是低血糖的出现情况的统计，评价12周治疗对2型糖尿病病人的安全性与普通制剂的对比。结果：12周治疗后，100例患者使用格列齐特缓释剂后和之前使用普通剂型对比的血糖化血红蛋白水平非常接近，组间差异无统计学意义，表明临床疗效相当。两组血糖日均值也相近。两组经血糖监测观察到低血糖发作次数差异无统计学意义。患者依从性的对比，格列齐特缓释片优于达美康普通片，并且无病人因不良事件出观察。观察中无严重不良事件发生。结论：格列齐特缓释剂与普通剂的疗效相似且安全性更佳。 [关键词] 达美康缓释片；2型糖尿病；疗效；安全性 [中图分类号] R587.1 [文献标识码]B [文章编号]1674-4721（2009）02（a）-019-02 Clinical observation of type 2 diabetes treatment by use of gliclazide modified release tablets instead of Gliclazide Ordinary Tablets WU Bang-tai, HOU Kai-jian (Department One of Internal Medicine, Hospital of Traditional Chinese Medicine of Shantou, Shantou515000,China) [Abstract] Objective: This thesis evaluates the effectiveness of general control of type 2 diabetes by taking Gliclazide Modified Release Tablets(30 mg per pill) for 12 weeks, compared with that of Gliclazide Ordinary Tablets. Mothods: 100 examples of type 2 diabetes were divided into 2 groups arbitrarily and received treatment. One group only took Gliclazide Ordinary Tablets at the beginning, but afterward change into using Gliclazide Modified Release Tablets. The other group was Gliclazide Ordinary Tablets users. After 12 weeks of treatment, the effectiveness and advantages of Gliclazide Modified Release Tablets to type 2 diabetes were evaluated refer to HbA1c and fasting blood-glucose. Meanwhile, the side-effect, especially the appearance of glucopenia, was taken statistics. And then the security of type 2 diabetes after 12 weeks of treatment was evaluated. Results: After 12 weeks of treatment, the HbA1c of the 100 examples who had used Gliclazide Modified Release Tablets was approaching to that of those who had used Gliclazide Ordinary Tablets, but there was no statistical significance in the disparities between the two gro